BCRX icon

BioCryst Pharmaceuticals
BCRX

Overview Fund Activity

241 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
241
Holders Change
+3
Holders Change %
+1.26%
% of All Funds
3.51%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
43
Increased
83
Reduced
69
Closed
38
Calls
$8.76M
Puts
$9.04M
Net Calls
-$281K
Net Calls Change
+$1.22M

Top Buyers

1
CP
1
Caligan Partners
New York
$28.4M
2
DM
2
Deerfield Management
New York
$50.3M
3
Alkeon Capital Management
3
Alkeon Capital Management
New York
$43.9M
4
KCM
4
Kynam Capital Management
New Jersey
$54.5M
5
Nuveen Asset Management
5
Nuveen Asset Management
Illinois
$27.8M

Top Sellers

1
BBA
1
Baker Bros. Advisors
New York
$468K
2
State Street
2
State Street
Massachusetts
$57.8M
3
B
3
Braidwell
Connecticut
$0
4
Citigroup
4
Citigroup
New York
$723K
5
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
NFSG
276
Newbridge Financial Services Group
Florida
– -$76 -15 Closed
DPW
277
DiNuzzo Private Wealth
Pennsylvania
– -$67 -13 Closed
TWP
278
TFO Wealth Partners
Ohio
– -$15 -3 Closed
8 9 10 11
12